The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Aclaris Therapeutics Inc listata cu simbolul US.ACRS ==Descriere companie== Aclaris Therapeutics, Inc. (https://www.aclaristx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on developing drug candidates for immuno-inflammatory diseases. Its drug candidates include ATI-450, ATI-1777, ATI-2138 and Undisclosed- Gut Restricted Program. Its ATI-450 is an investigational oral, small molecule selective mitogen-activated protein...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Aclaris Therapeutics, Inc. (https://www.aclaristx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on developing drug candidates for immuno-inflammatory diseases. Its drug candidates include ATI-450, ATI-1777, ATI-2138 and Undisclosed- Gut Restricted Program. Its ATI-450 is an investigational oral, small molecule selective mitogen-activated protein kinase-activated protein kinase 2, or MK2, inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777 is an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. Its ATI-2138 is an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, as al treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. | Aclaris Therapeutics, Inc. (https://www.aclaristx.com/) is a clinical-stage biopharmaceutical company. The Company is focused on developing drug candidates for immuno-inflammatory diseases. Its drug candidates include [[ATI]]-450, ATI-1777, ATI-2138 and Undisclosed- Gut Restricted Program. Its ATI-450 is an investigational oral, small molecule selective mitogen-activated protein kinase-activated protein kinase 2, or MK2, inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777 is an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. Its ATI-2138 is an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, as al treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||